31. May 2022

First public announcement of the Horizon trial , were Qmedics “back to the basics concept” with the innovative stent design that takes into account both movability and lesion characteristics.

With a portfolio consisting of three variances 4,5&6 French and two types PULL & FLEX - at the Linc congress in Leipzig. Tuesday, 7 June 2022 Room 3 Speakers corner : Latest results from clinical trials and innovations

First public announcement of the Horizon trial , were Qmedics “back to the basics concept” with the innovative stent design that takes into account both movability and lesion characteristics.

Treatment of the Femoro-Popliteal district with the innovative Exist NiTi Stent (QMEDICS) type Flex & Pull: the HORIZON clinical trial.

Marone E.M.1, Rinaldi L.F.2, Brioschi C.3, Glowinski J.4, Chlabicz M.5,Veroux P.6 ,Moelker A.7,Glauser F.8

  1. University of Pavia, Department of Vascular Surgery, Policlinico di Monza, Monza, Italy
  2. Medical University of Bialystock, University Clinical Hospital of Bialystok, Department of Vascular Surgery and Transplantation Bialystok, Poland
  3. University of Catania, University Hospital of Catania G. Rodolico -San Marco, Department of vascular surgery Catania, Italy
  4. University Erasmus MC, Rotterdam, University Medical center, Department of Radiology and Nuclear Medicine, Rotterdam, The Netherlands
  5. University of Genova, Geneva University Hospitals, Department of Vascular Surgery, Genève, Switzerland

First public announcement of the Horizon trial , were Qmedics “back to the basics concept” with the innovative stent design that takes into account both movability and lesion characteristics.

Aim: Self-expandable nitinol stenting can accomplish revascularization of severely diseased peripheral arteries with good clinical success and freedom from complications1. However, longer-terms patency rates in the femoro-popliteal district is still a concern, especially due to the extrinsic forces of flexion and torsion acting on these arteries with the movements of the lower limb2. At this level, heavy calcifications and lesions involving the distal superficial femoral artery (SFA) and the tract P1 of the popliteal artery represent the main technical challenges and require stents with dedicated structural characteristics 3,4.

 

 

 

 

First public announcement of the Horizon trial , were Qmedics “back to the basics concept” with the innovative stent design that takes into account both movability and lesion characteristics.

The aim of the Horizon study is to test on the femoro-popliteal district the two types of Exist NiTi Stent (Flex and Pull), whose design is.  meant to comply with the movability of the SFA and P1, while adapting to the specific characteristics of difficult atherosclerotic plaques.

 

 

 

Materials and methods:  The NiTi stent family is a self-expanding nitinol stent system made in 3 variants (4, 5 and 6F NiTi Stent System) and two types; PULL and FLEX. The PULL variant has a higher radial force and is meant for the treatment of difficult to reach, severely calcified lesions, thanks to its longitudinal movability. The FLEX variant has a high bending movability and it is indicated for moderately calcified and distal lesions. These devices have proved safety and effectiveness in large set investigations, but the overall rationale for this investigation is to provide long term outcomes and collect additional data including health economics data.

The Horizon study is a multicenter, prospective non-randomized clinical trial enrolling 250 patients affected by peripheral artery disease involving the SFA or P1 (TASC II A-B-C) and candidate to stenting with the Exist NiTi Stent in 5 European Centers. The choice of Pull or Flex type is based on the lesion characteristics: subjects requiring treatment of P1 are treated with

type Flex. Subjects requiring treatment of the SFA undergo an additional calcification review based on the Fanelli classification5. Subjects graded with Fanelli 1 or 2 are treated

with the Flex Stent. Fanelli grade 3 and 4 subjects receive the type Pull Stent. After implantation, clinical and instrumental follow-up after 6, 12 and 24 months will assess success and outcome durability. Follow-up evaluation includes  Rutherford/Fontaine Categorization, ABI, Walking Impairment- and Quality of Life questionnaire, and DUS imaging,

Results: Primary endpoints are freedom from perioperative adverse events and 12-months patency rate. Secondary endpoints include 6- and 12-months clinical success and technical success at 12 and 24 months. The criterion for success of the trial is defined by the primary endpoint, with a patency rate threshold of 50% after 12 months.

Conclusion: Stenting of the femoro-popliteal district poses important technical challenges related to high artery movability and complex, calcified lesions. The Horizon study will provide long-term outcomes of the innovative Exist NiTi stent with the two types PULL & FLEX  which allows for treatment of the SFA and P1 tailored on the patient’s anatomy and lesion characteristics.

References

  1. Das T. et al. Optimal therapeutic approaches to femoropopliteal artery intervention." Catheter Cardio Interven 2004; 63(1): 21-30.
  2. Laird JR. et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: Twelve month results from the RESILIENT randomized trial. Circulation: Cardiovascular Interventions 2010;3(3): 267-276.
  3. Erwin PA. et al Contemporary management of femoral popliteal revascularization. Intervent Cardiol Clinics 2014;3(4):517-530.
  4. Maleckis K. et al. Nitinol Stents in the femoropopliteal artery: A mechanical perspective on material, design, and performance. Ann Biomed Eng. 2018;46(5): 684–704.
  5. Fanelli, F. et al. Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease. Cardiovasc Intervent Radiol. 2014;37:898–907.

 


2022
31. May 2022

First public announcement of the Horizon trial , were Qmedics “back to the basics concept” with the innovative stent design that takes into account both movability and lesion characteristics.

Treatment of the Femoro-Popliteal district with the innovative Exist NiTi Stent (QMEDICS) type Flex & Pull: the HORIZON clinical trial. Marone E.M.1, Rinaldi …

28. February 2022

Qmedics is proud to announce the first Enrolment in the “HORIZON” trial for the Treatment of PAD

The Horizon study will provide information on the long-term outcomes of the innovative EXIST NiTi self- expandable stent with its two types of …


2021
30. November 2021

Qmedics has obtained the Good Manufacturing Practices (GMP) certificate for its quality control, cleanroom facility and medical device manufacturing activities at its Swiss-based facility in Zürich- Flurlingen in November 2021

I am very pleased that Qmedics AG has been able to achieve the GMP certification. A GMP certification in general is granted to …

19. May 2021

Our publication Safety and Efficacy of Peripheral Embolization with EASYX Liquid Embolic Agent: A multicenter Prospective Study was accepted by the Journal of Vascular Interventional Radiology.

The use of cyanoacrylates, used for embolization for a long period of time, has decreased in the last decades, they are currently still …

28. February 2021

First EasyX Case report in Nicosia General Hospital, Cyprus

A 64-year Old patient presented to the nephrostomy department of Nicosia General Hospital with chronic allograft nephropathy and elevation of the inflammatory markers …

31. January 2021

A milestone reached EASYX I trial closed successfully

COVID-19 has created challenges in every aspects of healthcare. Due to the current pandemic, the medical device industry has been under tremendous pressure …


2020
31. August 2020

Qmedics Peripheral stent system family

After two and a half years of hard work finally we present the new peripheral stent family. It was a difficult path: The …

30. July 2020

PTA Qmedics product family Manatee-Naga-Nova is launched

The rise in the prevalence of cardiovascular diseases and peripheral vascular diseases, adaptation to a sedentary lifestyle, better healthcare facilities are key factors …


2019
30. September 2019

Qmedics achieved to close with success the first investigator meeting

“Horizon” Clinical investigation of the Qmedics Exist NiTi Stent portfolio with the Flex & Pull type in adults with Peripheral Artery Disease (PAD). …

31. July 2019

NEW PRODUCT added to our Portfolio

The EASYX™ Liquid Embolic is a new injectable, precipitating polymeric agent for the obliteration of vascular spaces through direct puncture or catheter access …


2018
31. October 2018

New Organization for Qmedics

In 2016 the Board of Directors decided to sell the sister company of Qmedics, who was at the same time the biggest customer …

28. September 2018

Qmedics team at Cirse

Our travel did start with a strike of the taxi drivers, a delay in our shipment of workshop material- but as a team …

31. July 2018

First workshop: Endovascular treatments of PAD

With the organization of workshops the professionals get to understand the two stent types “ Pull & Flex”. The first workshop “Endovascular treatments …

30. March 2018

Exist & Manatee launched in “Der Schweiz”

As a Swiss company we are very pleased that our improved QM1 “Exist” a product entirely developed at our facility “made in Switzerland” …

3. January 2018

LINC congress: Presentation of our innovative product portfolio

Already a whole year qmedics R&D engineers are working on this concept and with success. The Finite element analysis (FEA), the bench testing …


2017
22. December 2017

Qmedics receives DIN EN ISO 13485:2016 Certificate

Qmedics is proud to announce its DIN EN ISO 13485:2016 certification. The company is now in the right to develop, manufacture and market …


Copyright © 2022 Qmedics AG. All rights reserved.

Watch the video